Scancell Holdings AI Stock Analysis
Want to see GB:SCLP full AI Analyst Report?
Scancell Holdings (SCLP) AI Stock Analysis
Scancell Holdings
(LSE:SCLP)
The overall score is heavily constrained by the company's precarious financial position, with a near-insolvent balance sheet and a cash runway of less than two years. While the clinical and regulatory progress for the lead asset iSCIB1+ is exceptional and represents a significant value driver, the immediate risk of dilutive financing and the deeply bearish technical trend weigh heavily on the near-term outlook. The company's future hinges entirely on successful financing or partnership deals to bridge the gap to its 2029 Phase III readout.
Scancell Holdings (SCLP) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 95.77M
- Dividend Yield
- ―
- Average Volume (3M)
- 216.62K
- Price to Earnings (P/E)
- -4.5
- Beta (1Y)
- -0.05
- Revenue Growth
- -100.00%
- EPS Growth
- -30.39%
- Country
- UK
- Employees
- 55
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Scancell Holdings Business Overview & Revenue Model
Company Description
Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The c...
Scancell Holdings Earnings Call Summary
The call conveyed strong clinical and regulatory progress—most notably the FDA IND clearance, compelling PFS data (74% at 16 months with a 24% delta), validated manufacturing and delivery, and multiple pipeline and partnered value drivers (including up to $630M in Genmab milestones). The primary negatives are financial (no revenue, interim net loss, and a cash runway into H2 2026) and the long, blinded Phase III timeline to a registrational readout in H2 2029 which necessitates near-term financing or milestone receipts. On balance, the positive clinical/regulatory milestones and clear commercial pathway outweigh the funding and timing headwinds.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided that iSCIB1+—which showed 74% PFS at 16 months (a ~24 percentage‑point delta versus historic ipi/nivo data with median PFS ≈11.5 months) from a Phase II translational dataset of ~140 patients—will move to a registrational Phase III two‑arm study of ~230 patients per arm (~460 total) with an adaptive design, IND cleared by the FDA, a surrogate primary endpoint (enabling accelerated approval), plans to pursue Fast Track and a Breakthrough designation (decision timeline ~2–3 months) and a target readout/commercialization window in H2 2029; financially, H1 (6 months to 31 Oct 2025) R&D spend was $6.2m, admin costs £2.7m, operating loss £8.9m, net loss £5.7m, cash £8.6m (including a £3.0m R&D tax credit) giving runway into H2 2026, while management pursues partnering/financing (including up to $630m of potential Genmab milestones), expects Modi‑1 data in H1, anticipates further Genmab/SC129 milestones this year, and notes patent protection to 2041 plus scalable manufacturing and a PharmaJet needle‑free delivery partnership.
Scancell Holdings Financial Statement Overview
Summary
Financial health is critically weak. The company is pre-revenue with persistent, deep operating losses and a negative equity balance sheet. Cash burn, while slightly improved, remains substantial, creating a high risk of requiring dilutive financing. The only minor positive is the high gross margin on sporadic revenue, which is entirely overshadowed by the severe cash drain and insolvent balance sheet.
Income Statement
8Very NegativeBalance Sheet
5Very NegativeCash Flow
15Very Negative| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 | Oct 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 4.71M | 0 | 5.27M | 0 |
| Gross Profit | -672.00K | -672.00K | 3.59M | -966.00K | 4.75M | -740.00K |
| EBITDA | -13.69M | -16.75M | -12.71M | -7.06M | -12.19M | -3.75M |
| Net Income | -17.90M | -17.90M | -12.27M | -5.86M | -11.94M | -2.06M |
Balance Sheet | ||||||
| Total Assets | 10.36M | 10.36M | 23.09M | 23.58M | 30.27M | 49.06M |
| Cash, Cash Equivalents and Short-Term Investments | 5.32M | 5.32M | 16.89M | 14.82M | 19.92M | 28.73M |
| Total Debt | 17.08M | 17.08M | 16.27M | 19.87M | 21.13M | 18.92M |
| Total Liabilities | 29.77M | 29.77M | 26.93M | 27.08M | 36.50M | 29.57M |
| Stockholders Equity | -19.41M | -19.41M | -3.83M | -3.50M | -6.23M | 18.11M |
Cash Flow | ||||||
| Free Cash Flow | -10.56M | -10.56M | -6.12M | -15.84M | -8.34M | -8.55M |
| Operating Cash Flow | -10.56M | -10.56M | -6.11M | -15.66M | -8.14M | -7.80M |
| Investing Cash Flow | 356.00K | 356.00K | -1.54M | 178.00K | 81.00K | -741.00K |
| Financing Cash Flow | -1.35M | -1.35M | 9.73M | 10.39M | -746.00K | 46.08M |
Scancell Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SCLP, the sentiment is Negative. The current price of 79.00 is below the 20-day moving average (MA) of 83.77, below the 50-day MA of 90.39, and below the 200-day MA of 129.83, indicating a bearish trend. The MACD of -3.35 indicates Positive momentum. The RSI at 29.70 is Positive, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SCLP.
Scancell Holdings Peers Comparison
Overall Rating
GB:4BB52Neutral
GB:SCLP49Neutral
GB:SAR47Neutral
GB:POLB42Neutral
GB:OBI40Underperform
GB:AREC33Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 52Neutral | GBP 100.70M | -4.53 | -316.73% | ― | -56.10% | -16.77% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | GBP 96.98M | -4.51 | 128.87% | ― | -100.00% | -30.39% | |
| 47Neutral | GBP 23.75M | -6.04 | -188.01% | ― | ― | 28.78% | |
| 42Neutral | GBP 48.10M | -7.88 | -71.28% | ― | ― | 31.58% | |
| 40Underperform | GBP 57.20M | -2.40 | -9999.00% | ― | 26.99% | 4.36% | |
| 33Underperform | GBP 34.43M | 143.00 | 3.75% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:SCLP | Scancell Holdings | 79.00 | -15.50 | -16.40% | |
| GB:SAR | Sareum Holdings | 14.50 | 1.50 | 11.54% | |
| GB:4BB | 4basebio UK Societas | 525.00 | -187.50 | -26.32% | |
| GB:POLB | Poolbeg Pharma Ltd. | 6.15 | 2.60 | 73.24% | |
| GB:AREC | Arecor Therapeutics PLC | 71.50 | -2.50 | -3.38% | |
| GB:OBI | Ondine Biomedical, Inc. | 8.25 | -3.00 | -26.67% |
Scancell Holdings Corporate Events
Scancell clears share consolidation as it readies AIM trading and deal push
PositiveScancell Holdings has confirmed that all resolutions at its latest general meeting were approved, paving the way for a share consolidation in which every 10 existing ordinary shares of 0.1 pence will be combined into one new ordinary share of 1 pence...
Scancell Issues Shares Ahead of Consolidation and Publishes 2026 Annual Report
NeutralScancell Holdings has issued seven new ordinary shares to chief executive Dr Phil L’Huillier to ensure its share capital is exactly divisible by ten ahead of a planned share consolidation on a 10-for-1 basis. The new shares, which represent a negligi...
Scancell Bolsters Cancer Immunotherapy Push With Nasdaq Move and $75m Funding
PositiveScancell reported progress across its immunotherapy pipeline, led by iSCIB1+, which has U.S. fast track status and regulatory clearance in the UK for a Phase 3 trial in unresectable Stage IIIB or IV melanoma, with around 550 patients to be enrolled a...
Scancell Sets Vote on Neuphoria Merger and 10-for-1 Share Consolidation
PositiveScancell Holdings has released a circular and called a general meeting for 20 October 2026 to seek shareholder approval for its planned merger with Neuphoria Therapeutics and associated financing for a registrational Phase 3 study of melanoma therapy...
Scancell Secures Up to US$25m BlackRock Debt to Drive iSCIB1+ Phase 3
PositiveScancell Holdings has secured a loan facility of up to US$25 million from funds managed by BlackRock, adding a structured layer of debt financing to support its planned Phase 3 development of lead melanoma candidate iSCIB1+ and complementing the prop...
Scancell to Highlight Late-Stage Cancer Immunotherapy and U.S. Deal Plans at Wainwright Conference
PositiveScancell Holdings will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, with management hosting in-person investor meetings and providing a webcasted presentation accessible via the company’s website for...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026
